Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WPC03
- Development stage
- Preclinical
- Lead developer
- Westlake Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
WPC03 is a small molecule inhibitor targeting the mitogen-activated protein kinase (MAPK) signaling pathway. Developed by Westlake Pharmaceuticals (Hangzhou) Co., Ltd., a biotechnology company associated with Westlake University, WPC03 is currently in the drug discovery stage for the treatment of various cancers. The MAPK pathway, which includes proteins such as RAS, RAF, MEK, and ERK, is frequently mutated or overactivated in human malignancies, driving uncontrolled cell proliferation and survival. By inhibiting this pathway, WPC03 is intended to suppress tumor growth and overcome resistance to other therapies.
- Other names
- WPC03WPC-03WPC 03
02
Targets
MEK
Beyond the preview
Go deeper on WPC03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WPC03.